Move over CAR-T: The potential of NK cells in cell therapy

On today’s podcast, Dr. Fred Aslan, CEO of Artiva Biosciences, joins host Jonah Comstock to talk more about this newer avenue in cell therapy. They discuss the potential of NK cells to provide effective allogeneic cell therapy, the potential of the therapy in auto-immune disease, and the importance of a robust manufacturing process that can get a high number of doses from a small amount of donated tissue.